1 Dytfeld D, Dyszkiewicz W, Meissner RK: Rozwój pomostowania aortalno-wieńcowego oraz sposobów śródoperacyjnej protekcji mięśnia sercowego. Now Lek 2006;75:404-6
2 Gu YJ, Boonstra PW: Selection of priming solutions for cardiopulmonary bypass in adults. Multimedia Manual of Cardiothoracic Surgery 2006; January 9
<doi:10.1510/mmcts.2005.001198>
3 Kucewicz E, Czech B, Pawlak S: Przydatność roztworów hydroksyetyloskrobi w leczeniu chorych poddawanych operacjom serca z użyciem krążenia pozaustrojowego. Anest Intens Ter 2002;3:207-10
4 Lilley A: The selection of priming fluids for cardiopulmonary bypass in the UK and Ireland. Perfusion 2002;17:315-19
5 Larsen R: Anestezjologia. Red. Kübler A. Urban & Partner, Wrocław. 2003:727-53
6 Zander R: Leczenie Płynami. MedizinischeVerlagsgellschaft mbH, Melsungen 2006
7 Wilcox CS: Regulation of renal blood flow by plasma chloride. J Clin Invest 1983;71:726-35
8 Wilkes NJ, Woolf R, Mutch M, Mallett SV, Peachey T, Stephens R, Mythen MG: The Effects of Balanced Versus Saline-Based Hetastarch and Crystalloid Solutions on Acid-Base and Electrolyte Status and Gastric Mucosal Perfusion in Elderly Surgical Patients. Anesth Analg 2001;93:811-16
9 Durek G: Okołooperacyjna terapia płynowa. Medipress 2006
10 Durek G: Hipowolemia – rozpoznanie i leczenie. [w:] Układ krążenia w anestezjologii i intensywnej terapii. Wykłady Kursu Doskonalącego nr 2, FEEA, Ośrodek Regionalny we Wrocławiu 2007:69-83
11 Westphal M, James MF, Kozek-Langenecker S, Stocker R, Guidet B, Van Aken H: Hydroxyethyl starches, different products – different effects. Anesthesiology 2009;111:187-202
12 Ernest D, Belzberg AS, Dodeck PM: Distribution of normal saline and 5% albumin infusions in septic patients, Crit Care Med 1999;27:46-50
13 Russell JA, Navickis RJ, Wilkes MM: Albumin versus crystalloid for pump priming in cardiac surgery: meta-analysis of controlled trials. J Cardiothorac Vasc Anesth 2004;18:429-37
14 Cochrane Injuries Group Albumin Reviewers: Human albumin administration in critically ill patients: systematis review of randomized controlled trials. Br Med J 1998;317:235-40
15 Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R, SAFE Study Investigators: A comparison of albumin and saline for fluid resuscitation in the intensive care unit, N Engl J Med, 2004;350:2247-56
16 Kozek-Langenecker S: Effects of hydroxyethyl starch solutions on hemostasis. Anesthesiology 2005;103:654-60
17 Wilkes MM, Navickis RJ, Sibbald WJ: Albumin versus hydroxyethyl starch in cardiopulm:onary bypass surgery: A meta-analysis of postoperative bleeding. Ann Thorac Surg 2001;72:527-33
18 Gallandat Huet RCG, Siemons AW, Baus D, van Rooyen-Butijn WT, Haagenaars JA, van Oeveren W, Bepperling F: A novel hydroxyethyl starch (Voluven) for effective perioperative plasma volume substitution in cardiac surgery. Can J Anaesth 2000;47:1207-15
19 Haisch G, Boldt J, Krebs C, Suttner S, Lehmann A, Isgro F: Influence of a new hydroxyethylstarch preparation (HES 130/0.4) on coagulation in cardiac surgical patients. J Cardiothorac Vasc Anesth 2001;15:316-21
20 Durek G: Nowe aspekty zastosowania koloidów w terapii płynowej. [w:] Układ krążenia w anestezjologii i intensywnej terapii. Wykłady Kursu Doskonalącego nr 2, FEEA, Ośrodek Regionalny we Wrocławiu 2007:197-204
21 Godet G, Lehot JJ, Janvier G, Steib A, De Castro V, Coriat P: Safety of HES 130/0,4 (Voluven®) in patients with preoperative renal dysfunction undergoing abdominal aortic surgery: a prospective, randomized, controlled, paralel-group multicentre trial. Eur J Anaestesiol 2008;12:986-94
22 Tiryakioglu O, Yildiz G, Vural H, Goncu T, Ozyazicioglu A, Yavuz S: Hydoxyethyl starch versus Ringer solution in cardiopulmonary bypass prime solutions (a randomized controlled trial). J Cardiothorac Surg 2008;3:45 <doi:10.1186/1749-8090-3-45>
23 Shahbazi Sh, Zeighami D, Allahyary E, Alipour A, Esmaeeli MJ, Ghaneie M: Effect of colloid versus crystalloid administration of cardiopulmonary bypass prime solution on tissue and organ perfusion. Iran Cardiovasc Res J 2011;5:24-31
24 Lang K, Suttner S, Boldt J, Kumle B, Nagel D: Volume replacement with HES 130/0.4 may reduce the inflammatory response in patients undergoing major abdominal surgery. Can J Anaesth 2003;50:1009–16
25 Tamayo E, Alverez FJ, Alonso O, Castrodeza J, Bustamante R, Gómez-Herreras JI, Florez S, Rodriguez R: The inflammatory response to colloids and crystalloids used for pump priming during cardiopulmonary bypass. Acta Anaesthesiol Scand 2008;52:1204-12
26 Lang K, Boldt J, Suttner S, Haisch G: Colloids versus crystalloids and tissue oxygen tension in patients undergoing major abdominal surgery. Anesth Analg 2001;93:405–9
27 Standl T, Burmeister MA, Schroeder F, Currlin E, Schulte am Esch J, Freitag M: Hydroxyethyl starch (HES) 130/0.4 provides larger and faster increases in tissue oxygen tension in comparison with prehemodilution values than HES 70/0.5 or HES 200/0.5 in volunteers undergoing acute normovolemic hemodilution. Anesth Analg 2003;96:936–43
28 Sedrakyan A, Gondek K, Paltiel D, Elefteriades JA: Volume expansion with albumin decreases mortality after coronary artery bypass graft surgery. Chest 2003;123:1853-57
29 Rex S, Scholzt M, Weyland A, Busch T, Schorn B, Buhre W: Intra- and extravascular volume status in patients undergoing mitral valve replacement: crystalloid vs. colloid priming of cardiopulmonary bypass. Eur J Anaesthesiol 2006;23:1-9
30 Eising GP, Niemeyer M, Günther Th, Tassani P, Pfauder M, Schad H, Lange R: Does a hyperoncotic cardiopulmonary bypass prime affect extravascular lung water and cardiopulmonary function in patients undergoing coronary artery bypass surgery? Eur J Cardiothorac Surg 2001;20:282-9
31 Jimenez R, Ramirez R, Carracedo J, Aguera M, Navarro D, Santamaria R, Perez R, Del Castillo D, Aljama P: Cytometric bead array (CBA) for measurement of cytokines in urine and plasma of patients undergoing renal rejection. Cytokine 2005 7;32:45-50
32 Cram L.S: Flow cytometry, an overview. Methods Cell Sci 2002;24:1-9
33 Nuttall GA, Oliver WC: Con: Use of colloids in cardiac surgery. J Cardiothorac Vasc Anesth 2007;21:457-9
34 Bellamy MC: Wet, dry or something else? Br J Anaesth 2006;97:755-7
35 Durek G: Praktyczna płynoterapia okołooperacyjna. MediPage, Warszawa 2011
36 Rehm M, Haller M, Orth V, Kreimeier U, Jacob M, Dressel H, Mayer S, Brechtelsbauer H, Finsterer U: Changes in blood volume and hematocrit during acute preoperative volume loading with 5% albumin or 6% hetastarch solutions in patients before radical hysterectomy. Anesthesiology 2001;95:849-56
37 Jacob M, Chappell D, Rehm M: Clinical update: perioperative fluid management. Lancet 2007;369:1984-6
38 Eastwood GM, Dip G: Evaluating the reliability of recerded fluid balance to approximate body weght change in patients undergoing cardiac surgery. Heart Lung 2006;35:27-33
39 Boyle EM, Pohlman TH, Johnson MC, Verrier ED: Endothelial cel injury in cardiovascular surgery: the systemic inflammatory response. Ann Thorac Surg 1997;63:277-84
40 Kucewicz-Czech E, Puzio J, Zembala M, Przybylski R, Czech B, Wojarski J, Maruszewski M, Knapik P: Zespół poperfuzyjny – co nowego? Kardiochir Torakochir Pol 2007;4:45-48
41 Yap WW, Young D, Pethi V: Effects of gelatine and medium molecular weight starch as priming fluid in cardiopulmonary bypass – a randomised controlled trial. Perfusion 2007;22:57-62
42 Van der Linden PJ, De Hert SG, Deraedt D, Cromheecke S, De Decker K, De Paep R, Rodrigus I, Daper A, Trenchant A: Hydroxyethyl starch 130/0,4 versus modified fluid gelatin for volume expansion in cardiac surgery patients: the effects on perioperative bleeding and transfusion needs. Anesth Analg 2005;101:629-34
43 Vanhoonacker J, Ongenae M, Vanoversschelde H, Donadoni R: Hedroxyethyl starch 130/0,4 versus modified fluid gelatin for cardiopulmonary bypass priming: the effects on postoperative bleedeng and volume expansion needs after elective CABG. Acta Anaesth Belg 2009;60:91-7
44 Boks RH, Wijers MJ, Hofland J, Takkenberg JJ, Bogers AJ: Low molecular starch versus gelatin plasma expander during CPB: does it make a difference? Perfusion 2007;22:333-7
45 Ooi Su Min J, Ramzisham ARM, Zamrin MD: Is 6%hydroxyethyl starch 130/0,4 safe in coronary artery bypass graft surgery? Asian Cardiovasc Thorac Ann 2009;17:368-72
46 Boon NA, Colledge NR, Walker BR, [Red. Kokot F, Hyla-Klekot L]: Davidson Choroby wewnętrzne. Elservier, Urban & Partner 2009;wyd.1:926-35
47 Oczenski W, Werba A, Andel H: Podstawy wentylacji mechanicznej. 𝛼-medica press, Bielsko-Biała 2003
48 Kuitunen AH, Hynynen MJ, Vahtera E, Salmenpera MT: Hydroxyethyl starch as a priming solution for cardiopulmonary bypass impairs hemostasis after cardiac surgery. Anesth Analg 2004;98:291-7
49 Niemi TT, Suojaranta-Ylinen RT, Kukkonen SI, Kuitunen AH: Gelatin and hydroxyethyl starch, but not albumin, impair hemostasis after cardiac surgery. Anesth Analg 2006;102:998-1006
50 Schramko AA, Suojaranta-Ylinen RT, Kuitunen AH, Kukkonen SI, Niemi TT: Rapidly degradable hedroxyethyl starch solution impair blood coagulation after cardiac surgery: a prospective randomized trial. Anesth Analg 2009;108:30-6
51 Choi YS, Shim JK, Hong SW, Kim JC, Kwak YL: Comparing the effects of 5% albumin and 6% hydroxyethyl starch 130/0,4 on coagulation and inflammatory response when used as priming solutions for cardiopulmonary bypass. Minerva Anestesiol 2010;76:584-91
52 Kozek-Langenecker S, Jungheinrich C, Sauermann W, Van der Linden Ph: The effects of hydroxyethyl starch 130/0,4 (6%) on blood loss and use of blood products in major surgery: a pooled analysis of radomized clinical trial. Anesth Analg 2008;107:382-90
53 Casutt M, Kristoffy A, Schuepfer G, Spahn DR, Konrad C: Effects on coagulation of balanced (130/0,42) and non-balanced (130/0,4) hydroxyethyl starch orz gelatin compared with balanced Ringer’s solution: an in vivo study using two different viscoelastic coagulation tests ROTEM and SONOCLOT. Br J Anaesth 2010;105:273-81
54 Kozek-Langenecker S, Scharbert G: Effects of hydroxyethyl starch on hemostasis. Transfusion Alternatives in Transfusion Medicine 2007;9:173-81
55 Kozek-Langenecker S: Colloidal volume replacement therapy. UNI-MED, 2011:48-51
56 Wiedermann CJ, Dunzendorfer S, Gaioni LU, Zaraca F, Joannidis M: Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials. Critical Care 2010;14:R191 <doi:10,1186/cc9308>
57 Huter L, Simen TP, Weinmann L, Schuerholz T, Reinhart K, Wolf G, Amann KU, Marx G: Hedroxyethylstarch impairs renal functionand interstitial proliferation, macrophage infiltration and tubular damage in an isolated renal pefrusion model. Critical Care 2009;13:R23 <doi:10.1186/cc7726>
58 Davidson IJ: Renal impact of fluid management with colloids: a comparative review. Eur J Anaesthesiol 2006;23:721-38
59 Wiesen P, Canivet JL, Ledoux D, Roediger L, Damas P: Effect of hydrixyethylstarch on renal function in cardiac surgery: a large scale retrospective study. Acta Anaesth Belg 2005;56:257-63
60 Mahmood A, Gosling P, Vohra RK: Randomized clinical trial comparing the effects on renal function of hydroxyethyl starch or gelatin during aortic aneurysm surgery. Br J Surg 2007;94:427-33
61 Magder S, Potter BJ, Deverenne S, Fergusson D: Fluids after cardiac surgery: a pilot study of the use of colloids versus crystalloids. Crit Care Med. 2010;38:2117-24
62 Dart AB, Mutter TC, Ryth CA, Taback SP: Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database syst Rev 2010;20:CD007594
63 Sakr Y, Payen D, Reinhart K, Sipmann FS, Zavala E, Bewley J, Marx G, Vincent J-L: Effects of hydroxyethyl starch administration on renal function in critically ill patients. Br J Anaesth 2007;98:216-24
64 Suwalski G, Filipiak KJ: Uogólniona odpowiedź zapalna u chorych poddanych zabiegom chirurgicznej rewaskularyzacji mięśnia sercowego. Pol Prz Kardiol 2003;3:259-66
65 Bengi Celik J, Gormus N, Okesli S, Gormus ZI, Solak H: Methylprednisolone prevents inflammatory reaction occurring during cardiopulmonary bypass: effects on TNF- 𝛼, 6, IL-8, IL-10. Perfusion 2004;19:185-91
66 Collis RE, Collins PW, Gutteridge CN, Kaul A, Newland AC, Williams DM, Webb AR: The effect of hydroxyethyl starch and other plasma volume substitutes on endothelial cel activation; an in vitro study. Intensive Care Med. 1994;20:37-41
67 Xie J, Lv R, Yu L, Huang W: Hydroxyethyl starch 130/0,4 inhibits production of plasma proinflammatory cytokines and attenuates nuclear factor-𝜅Β activation and Toll-like receptors expression in monocytes during sepsis. J Surg Res 2010;160:133-8
68 Matharu NM, Butler LM, Rainger GE, Gosling P, Vohra RK, Nash GB: Mechanisms of the anti-inflammatory effects of hydroxyethyl starch demonstrated in a flow-based model of neutrophil recruitment by endothelial cells. Crit Care Med. 2008;36:1536-42
69 Kopeć M: Udział cytokin w mechanizmach patogenetycznych rozsianego krzepnięcia śródnaczyniowego. Acta Hematol Pol 1997;28(supl.):59-67
70 Łukaszewicz M, Mroczko B, Szmitkowski M: Znaczenie kliniczne interleukiny 6 (IL-6) jako czynnika rokowniczego w chorobie nowotworowej. Pol Arch Med Wewn 2007;117:247-51
71 Lehmann G, Marx G, Forster H: Bioequivalence comparsion between hydroxyethyl starcg 130/0,42/6:1 and hydroxyethyl starch 130/0,4/9:1. Drugs R D 2007;8:229-40
72 Sommermeyer K, Cech F, Schossow R: Differences in chemical structures between waxy maize- and potato starch-based hydroxyethyl starch volume therapeutics. Transfusion Alternatives in Transfusion Medicine 2007;9(3):127-33
73 Godier A, Durand M, Smadja D, Jeandel T, Emmerich J, Samama CM: Maize- or poato-derived hydroxyethyl starches: is there any thromboelastometric difference? Acta Anaesthesiol Scand 2010;54:1241-47